A large observational study published in the British Journal of Ophthalmology reveals that tadalafil, widely known as Cialis and prescribed for erectile dysfunction and enlarged prostates, is associated with a 22% higher risk of developing glaucoma, raising critical questions for long-term users worldwide.
When a widely utilized medication class intersects with a progressive, irreversible optic neuropathy like glaucoma, patients and providers alike must pause to review the epidemiological data objectively. The findings, led by researchers at the National Taiwan University Hospital, do not mean patients should abruptly discontinue their prescriptions. Instead, they demand a more rigorous, proactive clinical approach to ocular health.
In Plain English: The Clinical Takeaway
- What the study found: Men prescribed tadalafil for lower urinary tract symptoms showed statistically higher odds of developing glaucoma, ocular hypertension, and primary open-angle glaucoma over a five-year window.
- Understanding the risk: The relative risk increased by roughly 22% to 33% depending on the specific ophthalmic diagnosis, but the absolute risk for any individual patient remains low.
- Actionable next steps: Do not stop taking your medication. Discuss your personal glaucoma risk factors—such as a family history of eye disease or high eye pressure—with your eye care provider to determine if enhanced monitoring is necessary.
Unpacking the Epidemiological Data and Mechanism of Action
To understand why a medication designed for smooth muscle relaxation might impact the optic nerve, we must examine its mechanism of action. Cialis belongs to a pharmacological class known as phosphodiesterase type 5 inhibitors (PDE5i). These drugs promote erections by relaxing the blood vessels.
While this mechanism treats erectile dysfunction and benign prostatic hypertrophy (BPH), it also alters vascular dynamics throughout the body. Ocular blood flow and intraocular pressure regulation are delicately balanced systems. PDE5 inhibitors have been associated with eye health issues, prompting this latest deep dive into large-scale patient databases.
The research team, spearheaded by Chien-Chih Chou at the National Taiwan University Hospital in Taipei, analyzed data from January 2012 to December 2022. They evaluated nearly 74,000 men aged 40 or older. Half of the cohort had been prescribed tadalafil or a comparable PDE5 inhibitor for up to five years to manage urinary tract symptoms, such as sudden urinary urgency and frequency.
The statistical findings are precise. Men prescribed tadalafil demonstrated a 22% higher likelihood of developing glaucoma overall. Furthermore, they faced a 32% increased risk of ocular hypertension (elevated fluid pressure within the eye) and a 33% higher risk of primary open-angle glaucoma, which is the most prevalent form of the disease. Consequently, this group also exhibited a 33% higher rate of initiating glaucoma treatments.
| Ophthalmic Metric | Observed Risk Increase Among Tadalafil Users |
|---|---|
| Overall Glaucoma Risk | 22% higher |
| Ocular Hypertension | 32% higher |
| Primary Open-Angle Glaucoma | 33% higher |
| Initiation of Glaucoma Treatment | 33% higher |
Navigating Observational Limits and Regulatory Perspectives
Epidemiological associations require careful interpretation. Because the study was observational, it cannot definitively prove a direct cause-and-effect relationship between Cialis and optic nerve damage. Confounding variables—such as underlying vascular health, age-related comorbidities, and lifestyle factors—always play a role in retrospective database analyses.
.jpg?width=1200 "Photo: drugs.com")
Weighing these nuances, Dr. Jung Lee, clinical director for the Northwell Health Eye Institute at Bethpage in New York state, emphasized the importance of perspective when counseling patients. I don’t think that patients who take Cialis are going to be at risk for losing their eyesight,
Dr. Lee noted, adding, I don’t think there’s a contraindication to starting the medication just because of a possible risk of glaucoma.
Dr. Lee further explained that because glaucoma is frequently a silent disease, susceptible individuals should already be under regular surveillance. Because glaucoma is essentially a silent disease, any patient who has glaucoma risk factors… those patients already should definitely be screened beforehand and have just regular ongoing checkups,
she stated.
Contraindications & When to Consult a Doctor
Patients must never alter their pharmaceutical regimens without direct medical supervision. However, certain clinical profiles warrant heightened vigilance when considering or maintaining long-term tadalafil therapy:
- Individuals with a pre-existing diagnosis of glaucoma or ocular hypertension.
- Patients categorized as glaucoma suspects due to borderline intraocular pressures.
- Individuals with a documented family history of glaucoma.
- Patients presenting with high myopia, which independently increases structural vulnerability in the eye.
If you fit any of these profiles and take tadalafil regularly, consult your prescribing physician and an optometrist or ophthalmologist.
The Path Forward for Long-Term Patient Care
The intersection of urological care and ophthalmology highlights the complexity of modern pharmacology. Every therapeutic compound carries a metabolic and physiological footprint. For the millions of men managing benign prostatic hypertrophy or erectile dysfunction, tadalafil remains an effective and transformative medication.
The research out of Taipei does not invalidate its clinical utility. Instead, it refines our approach to patient safety. Enhanced ophthalmic monitoring for vulnerable populations transforms a statistical risk into an actionable preventive strategy. By maintaining open lines of communication with healthcare providers and committing to routine comprehensive eye exams, patients can protect their vision without compromising their quality of life.
References
- British Journal of Ophthalmology: Tadalafil use and risk of glaucoma and ocular hypertension. Published August 2026.
- Drugs.com HealthDay Reporting: Tadalafil (Cialis), Used for BPH and ED, Might Increase Glaucoma Risk. Updated August 2026.
- Northwell Health Eye Institute: Clinical commentary on PDE5 inhibitors and ocular monitoring protocols.
Keep reading
- NPB Roster Changes: Giants Demote Masaya Hagio and Tigers, Fighters Make Moves
- NASA: Earth Microbes Could Survive on Moon’s South Pole
- High Coffee Intake Linked to Lowered Bone Density in Postmenopausal Women: Can Moderate Caffeine Consumption Help?” Meta Description: Discover the surprising connection between coffee consumption and bone health in postmenopausal women. Learn how moderate caffeine intake may impact bone density and what you can do to protect your bones. Target Keywords: coffee and bone density, postmenopausal women, moderate caffeine consumption, bone health, osteoporosis (archyworldys.com)
- Get the Gilmore Girls Look with Dollar Tree Finds (archynewsy.com)
